With a large merger announced Sunday night, Medtronic's division in Mounds View for pacemakers and heart defibrillators would remain the company's largest single source of revenue, according to materials released Monday.

But just barely.

Devices to help patients with cardiac rhythm disease management would provide 18.2 percent of revenue for the new Medtronic.

The second-largest source of revenue would come from advanced surgical devices sold by Covidien, the Irish medical technology giant that Medtronic intends to acquire. The products would generate an estimated 17.8 percent of annual sales, according to slides presented during a conference call Monday morning with stock analysts.

Devices for cardiac rhythm management would account for a smaller slice of overall company sales, since they currently provide about 29 percent of Medtronic's annual revenue.

The companies announced Sunday night a $42.9 billion deal that would move Medtronic's executive offices to Ireland for tax purposes but would keep the operational headquarters in Fridley.

Medtronic and state officials say there won't be a down-side for the company's large operations in Minnesota, where the company employs more than 8,000.

"This is a highly strategic and compelling acquisition," Medtronic chief executive Omar Ishrak said Monday morning during the conference call. "This will put Medtronic in an unprecedented position.

Advertisement

"

Pacemakers and, more recently, implantable defibrillators have been the historical drivers of growth at Medtronic, which was founded in Minneapolis 65 years ago. But growth in the market for these heart devices has been sluggish for years.

The combined company would have $27.4 billion in revenue, including about $17 billion from Medtronic.